Mingde Biology: The stock may be subject to delisting risk warning

How will AI · Audit results influence the company’s subsequent stock performance?

Everyday Economic News AI Express, on April 7th, Mingde Biotech announced that the company’s audited total profit, net profit, and net profit after deducting non-recurring gains and losses are expected to be negative, and the revenue after deduction is below 300 million yuan, triggering the delisting risk warning as specified in Article 9.3.1, Paragraph 1, Item (1) of the Shenzhen Stock Exchange Listing Rules. The company’s preliminary estimates for 2025 show: total profit expected to lose 50 million to 75 million yuan, net profit attributable to shareholders of the listed company expected to lose 15 million to 25 million yuan, net profit after deducting non-recurring gains and losses expected to lose 100 million to 140 million yuan, and revenue after deduction is expected to be between 237 million and 297 million yuan. The audit work for the company’s 2025 annual report is still ongoing, and the final financial data will be based on the officially disclosed audited “2025 Annual Report”; if the specified conditions are met, the company will disclose a delisting risk warning announcement along with the annual report, and the stock will be suspended for one trading day after the announcement. From the day trading resumes, the stock will be subject to a delisting risk warning (commonly prefixed with “*ST”).